Simulations Plus Inc (SLP)
48.42
-0.83 (-1.69%)
USD |
NASDAQ |
Sep 23, 16:00
48.28
-0.14 (-0.30%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 979.81M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 23.60% |
| Valuation | |
| PE Ratio | 84.95 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 19.31 |
| Price to Book Value | 5.518 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.06 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 58.95% |
News
Headline
Wire
Time (ET)
Yahoo
09/21 09:35
MT Newswires
09/14 16:06
Yahoo
08/31 08:30
MT Newswires
08/29 05:50
MT Newswires
08/26 14:33
Yahoo
08/22 06:51
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/25/2022* | -- | Results | Q4 2022 | -- | 0.09 | -- | |
| 10/25/2022* | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 07/06/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/06/2022 | -- | Results | Q3 2022 | 0.20 | 0.17 | 17.65% | |
| 04/06/2022 | -- | Results | Q2 2022 | 0.21 | 0.12 | 75.00% | |
| 04/06/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 01/06/2022 | -- | Results | Q1 2022 | 0.15 | 0.09 | 67.11% | |
| 01/06/2022 | 17:00 EST | Earnings Call | Q1 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Simulations Plus, Inc; Cognigen Corporation; DILIsym, and Lixoft. It generates maximum revenue from Simulations Plus, Inc segment. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program that takes molecular structures as inputs; MedChem Designer and MedChem Studio. |
| URL | https://www.simulations-plus.com |
| Investor Relations URL | https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Health Information Services |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Oct. 25, 2022 (est.) |
| Last Earnings Release | Jul. 06, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 22, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.24 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.3637 |
| Yield to Sector | 0.2798 |
| Yield to Industry | 1.471 |
| Last Dividend Amt. | 0.06 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Jul. 22, 2022 |
| Yield (TTM) | 0.50% |
| Forward Yield | 0.50% |
| Payout Ratio | 40.92% |
| Cash Payout Ratio | 34.81% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 23, 2022.
Fundamentals
| Revenue (TTM) | 52.01M |
| Total Expenses (TTM) | 37.62M |
| Net Income (TTM) | 11.83M |
| Total Assets (Quarterly) | 186.22M |
| Total Liabilities (Quarterly) | 8.664M |
| Shareholders Equity (Quarterly) | 177.56M |
| Cash from Operations (TTM) | 18.25M |
| Cash from Investing (TTM) | -25.60M |
| Cash from Financing (TTM) | -9.099M |
Ratings
Profile
Edit
| Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Simulations Plus, Inc; Cognigen Corporation; DILIsym, and Lixoft. It generates maximum revenue from Simulations Plus, Inc segment. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program that takes molecular structures as inputs; MedChem Designer and MedChem Studio. |
| URL | https://www.simulations-plus.com |
| Investor Relations URL | https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Health Information Services |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Oct. 25, 2022 (est.) |
| Last Earnings Release | Jul. 06, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 22, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| SLP Tweets |